H. Grover ∙ A. Kumar ∙ M. Krishna ∙ P. Kumari ∙ S. Chandrashekaraiah ∙ A. Chakraborty ∙ J. Chauhan ∙ V. Patil ∙ V.P. Shyamasundar ∙ S. Kulkarni ∙ S. Kapoor ∙ J. Wingrove ∙ Y. Mundkur ∙ T. Patil ∙ C. Aggarwal Cellular Heterogeneity and Tertiary Lymphoid Structure Dynamics Predict Overall Survival in Immune Checkpoint Therapy-Treated NSCLC Patients , Journal of Thoracic Oncology, 20(10): 2025
Singh A, Horng H, Roshkovan L, Hershman M, Cohen EA, Aggarwal C, Carpenter EL, Katz SI, Kontos D. Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy , Sci Rep, 15: 2025,34591
Aggarwal C, Desai A, McConnell N, Cadirov N, Gustavsen G, Agarwal A, Chehab N, Kotapati S, Patel N. Clinician Perspectives on Digital and Computational Pathology: Clinical Benefits, Concerns, and Willingness to Adopt , Diagnostics (Basel), 15: 2025,2527
C. Aggarwal, D. Watson, P. Nair, A. Kumar, S. Khandelwal, J. Chauhan, S. Khanna, S. George, A. Dey, M. Patil, N. Ganesh, R. Purushottam, S. Kulkarni, P. G, D.A. Lala, S. Basu, S. Kapoor, M. Castro, J. Wingrove, T. Patil Computational Modeling of Comprehensive Genomic Profiling to Predict Chemotherapy Benefit in Advanced NSCLC , Journal of Thoracic Oncology, 20(10): 2025
N.F. Abdel Karim ∙ C. Aggarwal ∙ A. Kobayashi ∙ C. Pompili ∙ D. Molena ∙ E. Shum ∙ G. Friedrich ∙ H. Wakelee ∙ J.R. Brahmer ∙ L. Woldmann ∙ M. Boron ∙ N. Florez ∙ P. Garrido ∙ R. Shenolikar ∙ S. Peters14 ∙ J. Naidoo ∙ M.L. Hsu ∙ E. Felip Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review , Journal of Thoracic Oncology, 20(10): 2025
Anagnostou V, Aggarwal C. Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk Stratification , Cancer Discov, 15: 2025,1534-1536
Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sánchez-Hernández A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial , JAMA Netw Open, 8: 2025,e2518440
Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR. Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study , Clin Cancer Res: 2025
Roy AM, Bakouny Z, Dizman N, Paul MA, Ozay ZI, Lal BM, Nawfal R, Eid M, Chehade REH, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall AL, Murphy M, Owonikoko T, Xie W, Lee AI, Choueiri TK. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings , JCO Oncol Pract: 2025
Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, Charu Aggarwal Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions , American Society of Clinical Oncology Educational Book, 45(3): 2025
